| 1 |
Cao W，Xie S，Zhang L，et al.Expression of functional molecule on plasmacytoid dendritic cells is associated with HBsAg loss in HBeAgpositive patients during PEG-IFN α-2a treatment ［J］.Front Immunol，2022，13： 891424.
|
| 2 |
Gao N，Guan G，Xu G，et al.Integrated HBV DNA and cccDNA maintain transcriptional activity in intrahepatic HBsAg-positive patients with functional cure following PEG-IFN-based therapy ［J］.Aliment Pharmacol Ther，2023，58（10）： 1086-1098.
|
| 3 |
Zhang M，Chen H，Liu H，et al.The impact of integrated hepatitis B virus DNA on oncogenesis and antiviral therapy ［J］.Biomark Res，2024，12（1）：84.
|
| 4 |
Zheng JR，Wang ZL，Feng B.Hepatitis B functional cure and immune response ［J］.Front Immunol，2022，13：1075916.
|
| 5 |
Cao W，Lu H，Zhang L，et al.Functional molecular expression of nature killer cells correlated to HBsAg clearance in HBeAg-positive chronic hepatitis B patients during PEG-IFN α-2a therapy ［J］.Front Immunol，2022，13： 1067362.
|
| 6 |
Mohtashemi N，Dubé K，Thio C，et al.Patient acceptability of，and attitudes towards，hepatitis B cure research - A scoping review and identification of knowledge gaps ［J］.J Virus Erad，2023，9（4）： 100354.
|
| 7 |
Martinez MG，Villeret F，Testoni B，et al.Can we cure hepatitis B virus with novel direct-acting antivirals？ ［J］.Liver Int，2020，1： 27-34.
|
| 8 |
Boyd A，Dezanet LNC，Lacombe K.Functional cure of hepatitis B virus infection in individuals with HIV-coinfection： A literature review［J］.Viruses，2021，13（7）： 1341.
|
| 9 |
Xu R，Hu P，Li Y，et al.Advances in HBV infection and replication systems in vitro ［J］.Virol J，2021，18（1）： 105.
|
| 10 |
Li Y，Li S，Duan X，et al.Macrophage phenotypes and hepatitis B virus infection ［J］.J Clin Transl Hepatol，2020，8（4）： 424-431.
|
| 11 |
Duchemin NJ，Loonawat R，Yeakle K，et al.Hypoxia-inducible factor affects hepatitis B virus transcripts and genome levels as well as the expression and subcellular location of the hepatitis B virus core protein［J］.Virology，2023，586： 76-90.
|
| 12 |
Jiang B，Zhang Y，Li G，et al.Research progress on immune evasion of mycoplasma hyopneumoniae ［J］.Microorganisms，2024，12（7）： 1439.
|
| 13 |
Yee Mon KJ，Blander JM.TAP-ing into the cross-presentation secrets of dendritic cells ［J］.Curr Opin Immunol，2023，83： 102327.
|
| 14 |
Deng H，Gao H，Liu Y，et al.Comparative analysis of HBV basic core promoter/pre-core gene mutations and viral quasispecies diversity in HIV/HBV co-infected and HBV mono-infected patients ［J］.Acta Virol，2022，66（1）： 18-26.
|
| 15 |
Stone D，Long KR，Loprieno MA，et al.CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice ［J］.Mol Ther Methods Clin Dev，2020，20： 258-275.
|
| 16 |
Hayashi S，Isogawa M，Kawashima K，et al.Droplet digital PCR assay provides intrahepatic HBV cccDNA quantification tool for clinical application ［J］.Sci Rep，2022，12（1）： 2133.
|
| 17 |
Hong X，Hu J.Serum HBV RNA composition dynamics as a marker for intrahepatic HBV cccDNA turnover ［J］.J Med Virol，2020，92（8）：935-937.
|
| 18 |
Duan Z，Dong J，Liu Y，et al.Awareness of HBV functional cure and attitude toward related clinical trials among patients with chronic hepatitis B in China ［J］.Patient Prefer Adherence，2023，17： 2063-2072.
|
| 19 |
Sun H，Li Y，Zhang P，et al.Targeting toll-like receptor 7/8 for immunotherapy： recent advances and prospectives ［J］.Biomark Res，2022，10（1）： 89.
|
| 20 |
Ayithan N，Tang L，Tan SK，et al.Follicular helper T （T＜sub＞FH＜/sub＞） cell targeting by TLR8 signaling for improving HBsAg-specific B cell response in chronic hepatitis B patients ［J］.Front Immunol，2021，12： 735913.
|
| 21 |
Roca Suarez AA，Plissonnier ml，Grand X，et al.TLR8 agonist selgantolimod regulates Kupffer cell differentiation status and impairs HBV entry into hepatocytes via an IL-6-dependent mechanism ［J］.Gut，2024，73（12）： 2012-2022.
|
| 22 |
Weickert TW，Ji E，Galletly C，et al.Toll-Like receptor mRNA levels in schizophrenia： association with complement factors and cingulate gyrus cortical thinning ［J］.Schizophr Bull，2024，50（2）： 403-417.
|
| 23 |
Qiu J，Zou Y，Li S，et al.Discovery of benzimidazole substituted 1，2，4-oxadiazole compounds as novel anti-HBV agents with TLR8-agonistic activities ［J］.Eur J Med Chem，2022，244： 114833.
|
| 24 |
Abdolmohammadi-Vahid S，Baradaran B，Sadeghi A，et al.Effects of toll-like receptor agonists and SARS-CoV-2 antigens on interferon（IFN） expression by peripheral blood CD3+ T cells from COVID-19 patients ［J］.Exp Mol Pathol，2024，137： 104897.
|
| 25 |
Gane EJ，Dunbar PR，Brooks AE，et al.Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression ［J］.J Hepatol，2023，78（3）： 513-523.
|
| 26 |
Wang T，Kuley R，Hermanson P，et al.Immune complexes-mediated activation of neutrophils in systemic lupus erythematosus is dependent on RNA recognition by toll-like receptor 8 ［J］.Front Immunol，2024，15： 1515469.
|
| 27 |
Rawal P，Siddiqui H，Hassan M，et al.Endothelial cell-derived TGF-β Promotes epithelial-mesenchymal transition via CD133 in HBxonfected hepatoma cells ［J］.Front Oncol，2019，9： 308.
|
| 28 |
Moini M，Fung S.HBsAg loss as a treatment endpoint for chronic HBV infection： HBV cure ［J］.Viruses，2022，14（4）： 657.
|
| 29 |
Wooddell CI，Sanders D，Xu Z，et al.Characterization of hepatitis B virus transcripts in chronically HBV-infected chimpanzees and patients treated with ARC-520 siRNA demonstrates transcriptional silencing of cccDNA ［J］.Viruses，2024，16（12）： 1943.
|
| 30 |
Yao Q，Peng B，Li C，et al.SLF2 Interacts with the SMC5/6 complex to direct hepatitis B virus episomal DNA to promyelocytic leukemia bodies for transcriptional repression ［J］.J Virol，2023，97（7）：e0032823.
|
| 31 |
Hu K，Zai W，Xu M，et al.Augmented epigenetic repression of hepatitis B virus covalently closed circular DNA by interferon-α and small-interfering RNA synergy ［J］.mBio，2024，15（12）： e0241524.
|
| 32 |
Gupta SV，Fanget MC，MacLauchlin C，et al.Clinical and preclinical single-dose pharmacokinetics of VIR-2218，an RNAi therapeutic targeting HBV infection ［J］.Drugs R D，2021，21（4）： 455-465.
|
| 33 |
Yuen MF，Lim YS，Yoon KT，et al.VIR-2218 （elebsiran） plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection： a phase 2 study ［J］.Lancet Gastroenterol Hepatol，2024，9（12）： 1121-1132.
|
| 34 |
Gane E，Lim YS，Kim JB，et al.Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B： Results from randomized clinical trials ［J］.J Hepatol，2023，79（4）： 924-932.
|
| 35 |
Gupta AK，Taylor D，Nouri K.Lasers for treatment of androgenetic alopecia： an in-depth analysis ［J］.Lasers Med Sci，2025，40（1）： 108.
|
| 36 |
Janczura J，Brzdęk M，Dobrowolska K，et al.Steatotic liver disease in patients treated for chronic hepatitis B ［J］.Pol Arch Intern Med，2025，135（3）： 16942.
|
| 37 |
张思慧，崔富强.对慢性HBV 感染者全部治疗策略的卫生经济学考量 ［J］.中华肝脏病杂志，2024，32（5）： 406-410.
|
| 38 |
张敏，李静，王福生.儿童慢性乙型肝炎抗病毒治疗与临床治愈：进展与挑战 ［J］.中华肝脏病杂志，2021，29（12）： 1218-1223.
|
| 39 |
Han J，Guo Y，Zhang X，et al.Prevalence and associated factors of low-level viremia in chronic hepatitis B patients after long-term therapy with nucleos（t）ide analogs ［J］.Turk J Gastroenterol，2023，34（1）： 53-61.
|
| 40 |
艾小委，张梦阳，孙亚朦，等.从全球视角看慢性乙型肝炎扩大治疗新理念 ［J］.中华肝脏病杂志 2024，32（5）： 385-388.
|
| 41 |
汪梦兰，陈恩强.依从性影响慢性乙型肝炎的治疗 ［J］.中华肝脏病杂志，2022，30（11）： 1266-1269.
|
| 42 |
Huang CC，Wu KL，Liu JS，et al.Autonomic impairment in treatmentnaive patients with chronic hepatitis B and C infections［J］.Auton Neurosci，2022，238： 102928.
|
| 43 |
Liang H，Zheng X，Mao Q，et al.Comparative efficacy and safety of pegylated interferon-alpha monotherapy vs combination therapies with entecavir or tenofovir in chronic hepatitis B patients ［J］.Microbiol Spectr，2025，e0269424.
|
| 44 |
Wu JF，Tai CS，Chang KC，et al.Predictors of functional cure of chronic hepatitis B virus infection： A long-term follow-up study ［J］.Clin Gastroenterol Hepatol，2025，23（4）： 583-590.e3.
|
| 45 |
Gu F，Zeng K，Lan X，et al.Measuring HBV pregenomic RNA may be a potential biomarker to determine HBV functional cure in HIV/HBVco-infected patients with HBsAg loss ［J］.J Med Virol，2024，96（6）：e29762.
|